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Abstract
 
Tissue injury is a common sequela of acute virus infection localized to a specific organ such as
the lung. Tissue injury is an immediate consequence of infection with lytic viruses. It can also
result from the direct destruction of infected cells by effector CD8
 
 
 
 T lymphocytes and indi-
rectly through the action of the T cell–derived proinflammatory cytokines and recruited in-
flammatory cells on infected and uninfected tissue. We have examined CD8
 
 
 
 T cell–mediated
pulmonary injury in a transgenic model in which adoptively transferred, virus-specific cyto-
toxic T lymphocytes (CTLs) produce lethal, progressive pulmonary injury in recipient mice
expressing the viral target transgene exclusively in the lungs. We have found that over the 4–5
day course of the development of lethal pulmonary injury, the effector CTLs, while necessary
for the induction of injury, are present only transiently (24–48 h) in the lung. We provide evi-
dence that the target of the antiviral CD8
 
 
 
 T cells, the transgene expressing type II alveolar
cells, are not immediately destroyed by the effector T cells. Rather, after T cell–target interac-
tion, the type II alveolar cells are stimulated to produce the chemokine monocyte chemoat-
tractant protein 1. These results reinforce the concept that, in vivo, the cellular targets of spe-
cific CTLs may participate directly in the development of progressive tissue injury by activating
in response to interaction with the T cells and producing proinflammatory mediators without
sustained in vivo activation of CD8
 
 
 
 T cell effectors.
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Introduction
 
CD8
 
 
 
 T lymphocytes are well recognized as important
contributors to the adaptive immune response to virus in-
fection leading to virus clearance and recovery. The mech-
anism employed by these cells in clearing intracellular
pathogens include both cytolytic and noncytolytic activities
(1). CD8
 
 
 
 T lymphocytes likewise contribute to the devel-
opment of tissue injury during the host adaptive immune
response both in systemic viral infection and in virus infec-
tion localized to a particular organ or tissue (2–4). For ex-
ample, in experimental murine influenza infection, immu-
nodeficient mice were observed to have a more protracted
time to death than immunocompetant mice after lethal in-
tranasal infection (5–7). The relative contribution of lytic
virus infection and the virus-specific adaptive CD8
 
 
 
 T
lymphocyte response to that infection (in an organ such as
the lung) to cell death, tissue injury/inflammation, and the
development of organ dysfunction is, however, unclear.
 
Virus-specific CD8
 
 
 
 T lymphocytes normally circulate
in the blood or reside in secondary lymphoid tissues (e.g.,
lymph nodes, spleens, etc.; reference 8). After infection of a
tissue or organ like the lung, virus-infected APCs (primarily
dendritic cells) are believed to activate and migrate to lym-
phoid tissues where they stimulate naive, resting CD8
 
 
 
 T
cells to undergo antigen-specific activation and differentia-
tion into effector T cells. These effector CD8
 
 
 
 T cells then
migrate from the lymphoid tissue to the site of infection.
The recent development of technologies to enumerate anti-
gen-specific CD8
 
 
 
 T cells have provided detailed kinetic
information of the development and resolution of CD8
 
 
 
 T
cell response during local virus infection (9). Results from
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the application of these techniques to identify and quanti-
tate antigen-specific CD8
 
 
 
 T cells suggest that naive CD8
 
 
 
precursors activate and proliferate in response to virus infec-
tion in lymphoid tissues and accumulate in large numbers as
activated, fully-differentiated antigen-specific CTLs at the
primary site of infection (e.g., the lungs; references 10 and
11). The life span of these activated CTL effectors in in-
fected tissue appears to be very short. With the resolution of
infection, these CD8
 
 
 
 effector T cells decrease dramatically
in frequency at the site of infection (11–13).
To assess the impact of antigen-specific CD8
 
 
 
 effector
CTLs on lung inflammation and injury in the absence of
virus replication or the contribution of the early host innate
immune response to infection, we developed a transgenic
model of CD8
 
 
 
 T cell–mediated injury (14). In this model,
a viral transgene, the influenza HA, is selectively expressed
in pulmonary type II alveolar cells of transgene positive
mice using the lung-specific human surfactant-C promoter.
Injury is induced selectively in the lungs of transgene-posi-
tive mice by the adoptive transfer of cloned populations of
HA-specific CD8
 
 
 
 CTLs with defined effector activities.
Previous reports have established the HA specificity of the
injury induced, the characteristics of the lung inflammatory
infiltration and the contribution of specific CTL effector
mechanisms (e.g., cell-mediated cytolytic and specific T
cell cytokines) to the process (15, 16). These analyses indi-
cated that CD8
 
 
 
 T cell–induced injury in vivo does not
depend on the expression of the perforin or FasL lytic
mechanisms by the transferred effector CD8
 
 
 
 
 
T cells (16).
Recent evidence in this model further suggests that
chemoattractants produced by transgene positive alveolar
type II cells after CD8
 
 
 
 T cell transfer may contribute sub-
stantially to the development of lung inflammation (17).
This study was undertaken using this model: (i) to define
the kinetics of expression of inflammatory mediators de-
rived from the transferred T cells, the host inflammatory
cells, and the host type II target cells during the evolution
of pulmonary injury; (ii) to determine the fate of the trans-
ferred effector CTLs in the lungs after transfer; and (iii) to
evaluate the impact of the CTLs on the fate and function of
the HA-expressing type II alveolar cell targets in vivo. The
results of this analysis reveal that effector CTL are rapidly
and selectively eliminated from lungs of transgene-positive
mice (within 24–48 h after adoptive transfer) before full
development of lung injury and inflammation. In addition,
while the expression of the T cell–specific inflammatory
mediator, IFN-
 
 
 
, falls concomitantly with effector CTL
elimination from the lungs, the expression of other media-
tors (e.g., TNF-
 
 
 
 and monocyte chemoattractant protein
[MCP]-1) is sustained throughout the evolution of lung in-
jury. Finally, we provide evidence that the transgene-
expressing type II alveolar cells are not destroyed in vivo as
a result of the initial encounter with the effector T cells.
Rather, these cells appear to be activated by the encounter
with the CTLs, and remain functional to express MCP-1
for several days after the disappearance of the CTLs. These
observations support the hypothesis that alveolar target cells
may actively participate in the development of lung injury
 
and inflammation triggered by CD8
 
 
 
 T cell recognition.
Furthermore, these findings reinforce the view that imme-
diate destruction of the antigen-bearing target cells is not
the necessary outcome of effector CTL encounter with tar-
get cells in vivo, and that the progression of tissue-specific
injury in response to CTL recognition does not require the
continued presence of CTLs and the sustained expression
of CTL effector activity in that tissue.
 
Materials and Methods
 
Mice.
 
H2
 
d
 
 haplotype HA-transgenic mice expressing the
A/Japan/57 influenza HA under the transcriptional control of the
surfactant protein C (SPC)
 
*
 
 promoter were produced and charac-
terized as described (14). Severe combined immunodeficient
(SCID) H2
 
d
 
 mice on the BALB/c background were initially pur-
chased from the Jackson ImmunoResearch Laboratories. The HA
transgene was transferred from conventional (immunocompetent)
mice into the SCID background by standard breeding. Transgene-
negative litter mates of immunocompetent and SCID transgene-
positive animals served as control recipients for these experiments.
 
CD8
 
 
 
 T Lymphocytes.
 
The CD8
 
 
 
 T lymphocyte clone, D4,
specific for the HA210–219 epitope of the A /Japan/57 HA was
used in the adoptive transfer studies described in this report. The
clone was isolated by limiting dilution and propagated in vitro us-
ing irradiated splenocytes infected with A/Japan/57 (or A/Guiy-
ang/57/var17) virus as described previously (18). On day 5 after in
vitro stimulation of the cloned CD8
 
 
 
 CTL, activated T cells were
separated from irradiated splenocyte stimulators by density gradient
separation. In some experiments the isolated cloned CD8
 
 
 
 T cells
were labeled with the vital dye CFDA-SE (Molecular Probes) as
described previously (18) before adoptive transfer into mice.
 
Analysis of Pulmonary Cytokine, Chemokine, and Surfactant Gene
Expression.
 
At the indicated times after transfer of cloned D4
CTLs into HA
 
 
 
 and HA
 
  
 
recipient mice, animals were killed and
lungs harvested. Total lung RNA was purified from homogenized
lung tissues by extraction with Trizol (Life Technologies). Lung
RNA from individual mice was prepared and analyzed separately.
Cytokine and chemokine mRNA were quantitated by a RNase
protection method using the RiboQuant multiprobe RNase pro-
tection assay (RPA) system (BD PharMingen) according to the
manufacturer’s instructions. Briefly, mRNA-specific RNA probes
labeled with 
 
32
 
[P] UTP were synthesized using multi-probe tem-
plate sets designed for the indicated murine chemokine and cy-
tokine genes. Each probe set was hybridized separately with pul-
monary mRNA from transgene positive or negative recipient
mice. Surfactant protein B (SP-B) gene expression was quanti-
tated in a similar manner using a 330 base pair complementary
RNA probe for the murine SP-B mRNA generated from a
cloned SP-B cDNA (provided by Jeffrey Whittset, Cincinnati
Children’s Hospital). Hybridizations were performed overnight at
56
 
 
 
C before RNase treatment and electrophoresis of the pro-
tected RNA fragments on 5% polyacrylamide sequencing gels.
 
Identification and Enumeration of Transferred CD8 T Cells In
Vivo.
 
At the indicated times after adoptive transfer into the tail
veins of recipient mice, animals were killed and the chest and ab-
 
*
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dominal cavities were exposed. After transection of the abdomi-
nal aorta, 3 mL of cold heparinized saline was introduced into the
right ventricle in order to perfuse the pulmonary vasculature and
remove any residual transferred T cells remaining within the pul-
monary circulation. Lungs were then excised, minced, and ex-
truded through a wire mesh screen to produce a cell suspension.
Preliminary experiments in which intact lungs or lung fragments
were digested with collagenase, dyspase, and/or DNase before or
after extrusion of the lung tissue through the wire mesh screen
showed no difference in the yields of transferred T cells isolated
from the lung parenchyma.
The CD8
 
 
 
 T cells isolated from the lung parenchyma were
enumerated by flow cytometry using monoclonal anti-CD8 anti-
body 53–6.7 (BD PharMingen) and H2-K
 
d
 
 tetramers containing
the synthetic HA210–219 peptide epitope or a control H2-K
 
d
 
tetramer loaded with a K
 
d
 
 binding peptide from the murine Janus
kinase (Jak)-1 protein. The preparation of these tetramers and
their use in the identification of the HA210–219 specific CTL
clone, D4, have been described previously (18). CD8
 
 
 
 T cells
present in the lung parenchyma which produced IFN-
 
 
 
 in re-
sponse to short-term in vitro stimulation with the HA210–219 or
control HA204–212 peptides were identified and enumerated by
intracellular cytokine staining using fluorescent antibody (anti-
IFN-
 
 
 
, XMG1.2; BD PharMingen). Flow cytometry analysis of
CD8
 
 
 
 T cells present in the lungs which were dye-labeled and
stained against intracellular cytokine or with tetramer was per-
formed using a FACSCaliber™ analytical flow cytometer (Bec-
ton Dickinson). Data acquisition and analysis was performed us-
ing the CELLQuest™ software package.
 
Morphological Analysis of Lung Tissue.
 
At the indicated time
after adoptive transfer, transgene-positive mice were killed. For
light microscopy and immunohistochemistry, lungs of mice were
inflated with air before fixation in 10% neutral buffered formalin.
Sections were cut from fixed, paraffin-embedded tissue, and
stained with H&E. For immunohistochemistry, formalin-fixed,
paraffin-embedded tissues were cut into 5-
 
 
 
m sections and dried
onto poly-L-lysine-coated slides. The tissue sections were incu-
bated in a steamer containing 1X target retrieval solution
(DAKO) for 20 min and then deparaffinized with xylenes. Next,
the deparaffinized sections were incubated with peroxide block,
avidin block, biotin block, and powerblock solutions (all supplied
by Biogenex). T cells were detected using anti-CD5 mAb (2.5
 
 
 
g/ml) and macrophages were labeled with Mac-3 mAb (2.0 
 
 
 
g/
ml) (BD PharMingen). The FITC-conjugated primary antibodies
were labeled with biotinylated anti-FITC antibody (5 
 
 
 
g/ml)
(Molecular Probes), followed by HRP-conjugated streptavidin
(BioGenex). The slides were developed using 3,3
 
 
 
-diaminoben-
zidine tetrahydrochloride chromogen solution, counterstained
with Mayer’s hematoxylin, and covered with Supermount
mounting medium (all reagents from BioGenex). For in situ hy-
bridization, lungs were perfused through the trachea with 10%
neutral buffered formalin and fixed. Tritiated riboprobes for
MCP-1 and influenza transgene mRNA were prepared as de-
scribed previously (17). In situ hybridization was performed for a
2–4-wk period before analysis.
 
Results
 
Bystander Lymphocyte Involvement in Pulmonary Injury.
 
To evaluate CD8
 
 
 
 T lymphocyte-mediated injury to the
pulmonary parenchyma in the absence of any other inflam-
matory stimuli, we developed a transgenic mouse model
(SPC-HA transgenic mice) in which the gene encoding the
type A influenza HA (A/JAPAN/305/57, H2/N2) is ex-
pressed under the control of the SPC promoter resulting in
specific expression of the HA protein in type II alveolar
pneumocytes (14). We reported previously that adoptive
transfer of pure clonal populations of influenza HA-specific
CD8
 
 
 
 effector CTLs into SPC-HA mice results in signifi-
cant pulmonary injury, leading to progressive decrements
in pulmonary function, considerable morbidity, and ulti-
mately (at higher doses of transferred cells) mortality (refer-
ences 14 and 15; Fig. 1). This CD8
 
 
 
 T cell–mediated in-
jury is characterized by the progressive accumulation of
inflammatory cells in the alveolar walls and alveolar spaces
(references 15 and 16; Fig. 2). Initially after T cell transfer
(days 1–2), histologic changes in recipient lungs are subtle
with evidence of extravasation of erythrocytes, a mild neu-
trophil infiltration, and morphologic evidence of increased
alveolar capillary permeability. Over time (days 3–5), there
is a massive influx of mononuclear cells into the alveolar
walls and surrounding the small airways, and this massive
mononuclear infiltration is temporarily associated with the
progressive decrements in pulmonary function, with mor-
bidity, and ultimately, with death. Using the same experi-
mental model, Zhao et al. reported that the majority of the
cells in this late infiltrate expressed macrophage markers al-
though there were also appreciable numbers of CD8
 
 
 
 and
CD4
 
 
 
 T cells evident (17).
Although the progressive injury observed in this model
was assumed to be due to the specific recognition and
rapid destruction of the transgene-expressing alveolar type
II cells by the transferred CD8
 
 
 
 CTLs (with a secondary
Figure 1. Morbidity and mortality of SPC-HA+ and SPC-HA  SCID
mice after CTL T cell transfer. (A) Kinetics of weight loss (as percentage
of starting weight) in HA+ SCID mice ( ), HA+ wild-type mice ( )
and HA-SCID mice ( ) after adoptive transfer of 10   106 cloned D4
CTLs. (B) Time course of survival of mice in A. Weight values are
means of four recipient animals per group and are representative of three
independent experiments. 
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influx of macrophages as a result of acute injury), the pres-
ence of a significant lymphocyte infiltrate in the lung pa-
renchyma at late times after CTL transfer raised the pos-
sibility that lymphoid cells of recipient origin could
contribute to the injury, possibly as a result of bystander
cell recruitment and activation in the inflamed lungs.
Therefore, we wanted to first determine whether there
was any contribution of lymphocytes of recipient origin to
the pulmonary injury induced by the transferred HA-spe-
cific CTLs. To examine this issue, we performed adoptive
transfer of HA-specific CD8
 
 
 
 effector CTL into a panel of
SPC-HA
 
 
 
 immunodeficient SCID mice and, in parallel,
into a panel of conventional SPC-HA
 
 
 
 mice [as well as
congenic SCID mice lacking the transgene (SCID-HA
 
 
 
)].
As Fig. 1 depicts, adoptive transfer of the effector CTL
into SCID-HA
 
  
 
mice had no effect on the survival of
these animals (up to 21 d after transfer) and did not result
in morbidity as measured by weight loss. This result is
consistent with our earlier finding that the development of
pulmonary injury and mortality in this model is dependent
upon the expression of the HA transgene in the lungs of
recipient mice (14). By contrast, both conventional SPC-
HA
 
 
 
 mice and the immunodeficient SCID-HA
 
 
 
 mice
exhibited significant weight loss by day 3 after CTL trans-
fer (Fig. 1 A), with loss of 20% of body weight by days
4–5 after transfer. Lethal injury occurred in both HA
 
 
 
groups, and the death of all recipients was observed in
both groups by days 4–5 after adoptive transfer (Fig. 1 B).
This result indicated that recipient lymphocytes do not
contribute significantly to the development of this CD8
 
 
 
T cell–mediated pulmonary injury and inflammation and
suggest that recipient mononuclear cells of monocyte/
macrophage origin are sufficient to orchestrate the inflam-
matory response in the lungs of SPC-HA
 
 
 
 mice after T
cell transfer.
Histologic confirmation was provided by harvesting the
lungs of SCID-HA
 
 
 
 recipients at day 3–4 after CTL trans-
fer, a time at which the mice were preterminal (Fig. 2). As
observed previously in conventional SPC-HA
 
 
 
 recipients
(14), the SCID-HA
 
 
 
 lung histology was characterized by a
dense infiltration of alveolar walls with inflammatory cells
consisting largely of mononuclear cells with few polymor-
phonuclear cells scattered throughout the lung parenchyma
(Fig. 2 A). Immunoperoxidase staining of fixed tissue re-
vealed that this mononuclear cell infiltrate consisted pri-
marily of Mac-3 antibody-staining cells, reflecting their
monocyte/macrophage origin (Fig. 2 B). Parallel staining
for cells of T lymphocyte origin (using anti-CD5 antibody)
revealed only occasional CD5
 
 
 
 cells presumably represent-
ing the adoptively transferred cloned CTLs (Fig. 2 C). No
inflammation was evident in the lungs of SCID-HA
 
 
 
 mice
after T cell transfer (data not shown).
 
Inflammatory Mediator Expression in the Lungs during the
Evolution of Pulmonary Injury.
 
The requirement for spe-
cific antigen recognition by the transferred CD8
 
 
 
 T cells to
induce pulmonary injury suggests that one or more of the
antigen-dependent effector functions of the T cells (i.e., di-
rect cytolysis and/or proinflammatory mediator release) are
needed to be expressed for the development of injury. Of
course, this does not preclude a contribution of nonlym-
phoid, innate inflammatory cells, or lung parenchymal cells
of recipient origin to the progression of injury, though
their recruitment and participation is also dependent upon
specific recognition of antigen by transferred CD8
 
 
 
 T cells.
Figure 2. Histologic evaluation
of lung morphology of SPC-HA+
SCID mice. (A) Representative H&E
section of lungs SPC-HA+ SCID
mice at day 3 after CTL transfer
showing dense mononuclear infiltrate
in alveolar walls. (B) Immunoperoxi-
dase staining of fixed lung section
with anti–MAC-3 antibody demon-
strating MAC-3+ cells in alveolar
walls and alveolar spaces. (C) Immu-
noperoxidase staining of serial section
of lung tissue examined in B with
anti-CD5 antibody. Arrow indicates
single CD5+ cell detected in this sec-
tion. Original magnification:  250. 
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Therefore, it was of interest to examine the expression of
inflammatory mediators in the lung parenchyma after T cell
transfer and the relationship of mediator expression to in-
flammation and injury. We examined the kinetics of ex-
pression of several important cytokine and chemokine
genes in lung after T cell transfer into conventional SPC-
HA
 
 
 
 transgenic mice and control SPC-HA
 
 
 
 recipients by
RPA. The results are shown in Figs. 3 and 4. In short-term
kinetic analysis, lungs were harvested from SPC-HA
 
 
 
 and
control SPC-HA
 
 
 
 mice at 6, 24, and 48 h after T cell
transfer and total lung RNA was isolated for analysis of cy-
tokine gene expression (Fig. 3 A). In HA
 
 
 
 control mice,
expression of the T cell–specific cytokine, IFN-
 
 
 
, as well
as, the cytokine TNF-
 
 
 
 (which is produced by both mac-
rophages and the CD8
 
 
 
 T cells) was detected at low levels
at 6 h after T cell transfer, but the level of these cytokine
transcripts dropped to low or undetectable levels by 24–48 h.
In the lungs of HA
 
 
 
 transgenic recipients, a high level of
TNF-
 
  expression was readily detectable at the 6 h time
point and was sustained  48 h. In contrast, IFN-  expres-
sion was initially very high at the 6 h time point. While still
detectable at 24 and 48 h, IFN-  expression progressively
diminished over time. The level of expression of the cyto-
kines LT- , TGF- 1, TGF- 2, and migration inhibitory
factor in the lungs of both HA  and HA  mice were either
unchanged over time or demonstrated a minimal increase
in HA  lungs.
Since pulmonary injury induced by the transferred T
cells becomes progressively more severe over time, we ex-
tended this RPA analysis of TNF-  and IFN-  expression
in the lungs of SPC-HA  mice to include 72 and 96 h
time points. Representative results of this analysis are
shown in Fig. 4 A, and demonstrate that TNF-  expres-
sion was sustained at the 72 and 96 h time points in HA 
recipients, while expression of IFN-  was found to fur-
ther decrease progressively over time to very low levels by
96 h (day 4) after cell transfer. As expected, expression of
neither cytokine gene was detectable at these later time
points in the lungs of HA  nontransgene recipients (data
not shown).
A parallel, short-term kinetic analysis of selected che-
mokine gene expression in the lungs of HA  and HA  re-
cipients early after T cell transfer revealed a pattern similar
to that recently published using the same model (17). As
Fig. 3 B demonstrates, there was transient, low level ex-
pression of the MCP-1 CC chemokine and the IFN-
dependent inducible protein (IP)-10 CXC chemokine genes
in HA  recipients at 6 h after T cell transfer which dimin-
ished to background levels by 24–48 h. In HA  recipients,
there was dramatically increased expression of MCP-1
which diminished slightly over time, but was still sustained
at the 48 h time point. In contrast, while the expression of
IP-10 was also initially very high, IP-10 fell over 24–48 h
in parallel with IFN-  expression. Expression of Ltn, MIP-
Figure 3. Early kinetics of cytokine and chemokine
gene expression in SPC-HA+ and SPC-HA  mice. At the
indicated time (in h) after transfer of 8–10   106 cloned
D4 CTLs, lungs of HA+ and HA  recipients were excised,
and RNA was extracted. (A) Time course of expression of
the indicated cytokine genes and housekeeping genes by
RPA. (B) RPA analysis of selected chemokine gene ex-
pression kinetics using the same RNA samples analyzed in
A. Data displayed represent lung RNA from two trans-
gene-positive (HA+) and transgene-negative (HA ), con-
ventional (immunocompetent) recipient mice at each time
point, and are representative of three independent RPA
analyses of gene expression.
Figure 4. Extended kinetic analysis of IFN- , TNF- , and MCP-1
gene expression in SPC-HA+ mice. (A) Representative RPA analysis of
the lung RNA at 6, 24, 48, 72, and 96 h after infection of 10   106
cloned D4 CTLs. (B) Companion analysis of MCP-1 gene expression de-
tected lung RNA from the donor mice examined in A. The level of ex-
pression of the housekeeping gene L32 is included as a control for RNA
loading. Comparable data was obtained in three independent experiments.1840 CTL Effector Activity in Lung Injury
1 , MIP-1 , and MIP-2 was detected exclusively in the
lung of the HA  recipients with either sustained expression
or gradually decreased expression over 48 h. Expression of
regulated upon activation, normal T cell expressed and se-
creted (RANTES) was comparable in HA  and HA  re-
cipients. Extended kinetic analysis of MCP-1 gene expres-
sion to the 72 and 96 h time points (Fig. 4 B) reveals
detectable MCP-1 expression as late as 96 h after T cell
transfer. So, like TNF- , the gene expression of the che-
mokine MCP-1 gene (and several other chemokine genes)
was sustained late in the course of injury development (days
3–4) when inflammation was most severe. The expression
patterns for the other chemokines examined at 72 and 96 h
in HA  recipients closely paralleled the tempo established
over the first 48 h with MIP-1  maintaining a sustained
level of expression while MIP-1  and IP-10 expression fell
to undetectable levels at the later time points (data not
shown). A limited analysis of the kinetics of lung cytokine
and chemokine gene expression during injury development
was also performed in SP-C HA  SCID recipients. The
pattern of inflammatory mediator expression was compara-
ble to that of conventional SP-C HA  mice with a sus-
tained elevation of MCP-1 and TNF-  expression and a
progressive fall in IFN-  expression (data not shown); al-
though in SP-C HA  SCID recipients, low level IFN- 
expression was still detectable out to 72 h because of the
similarity in injury development and cytokine/chemokine
gene expression between conventional and SCID recipi-
ents and because of the limited availability of SPC-HA 
SCID mice, subsequent studies described below were per-
formed in conventional SP-C HA  and HA  mice.
Fate and Functional Activity of Adoptively Transferred T Cells
Resident in the Lung. The cytokine IFN-  is primarily a
product of activated T lymphocytes and NK cells and is
produced in response to the HA target antigen by the
CD8  CTL clone used in these transfer studies (unpub-
lished data). Since recipient T lymphocytes appear to play a
minimal role in the development of pulmonary injury me-
diated by HA-specific CTLs, the transferred T cells were
the likely source of the IFN-  gene expression detected in
the lungs of the HA  mice. Therefore, it was noteworthy
that IFN-  expression in the lungs decreased rapidly over
time in spite of the sustained expression of TNF-  and
MCP-1 and the progressive development of pulmonary in-
flammation. These results raised the possibility that the
HA-specific CD8  T cells may not be present in the lungs
(or at least may not be functioning) at later times after
transfer into SPC-HA  mice and prompted us to examine
the fate of adoptively transferred T cells resident in the
lungs of HA  and HA  recipients.
To address this issue, the cloned CTLs were labeled with
the cell division sensitive, intracellular vital dye, CFDA-SE
(19) before adoptive transfer into HA  transgenic and non-
transgenic mice. Lungs were removed at serial time points
after cell transfer and the fate of labeled cells resident in lung
homogenates was enumerated by flow cytometry. As Fig. 5
demonstrates, labeled cells were readily isolated from the
lung parenchyma of both SPC-HA  (Fig. 5 A) and non-
transgenic control recipients at 24 h after transfer (Fig. 5 B).
The uniform pattern of staining intensity suggests that cell
division had not occurred in the lungs of either recipient
group at day 1 after transfer (20). By 48 h after cell transfer,
we noted two patterns of cell accumulation in HA  trans-
gene positive mice. In some recipients (Fig. 5 C), labeled
cells could be detected at a low frequency and, based upon
dye fluorescence intensity, had undergone several rounds of
cell division. In the majority of recipients, however, dye-
labeled cells were rarely identified (data not shown). In con-
trol recipients (Fig. 5 D), dye-labeled cells were detected in
the lung parenchyma at 48 h and the uniformity of fluores-
cence intensity suggests that the transferred T cells had un-
dergone few, if any, divisions at this time. These data are
representative of four independent experiments.
By days 4–5 after T cell transfer, at a time when surviving
transgene positive mice were severely ill, few if any labeled
T cells were detected in lung homogenates from any HA 
recipients (Fig. 5 E). By contrast, labeled cells were still
present in the lung parenchyma of the control nontrans-
genic mice, and the pattern of fluorescence intensity sug-
gested that these cells had undergone a very limited number
of cell divisions (1 or 2) in the absence of antigen (Fig. 5 F).
The paucity of labeled CD8  T cells detected in the
lung parenchyma by 4–5 d after transfer in HA  recipients
was likely due to their death in situ as a result of activa-
tion-induced cell death triggered by specific antigen rec-
Figure 5. Kinetics of CFDA-SE–labeled CTL accumulation in the
lungs. D4 CTLs were labeled with the dye CFDA-SE before adoptive
transfer of 10   106 T cells into HA transgene-negative (control) and
SPC-HA+ (HA transgenic) recipients. On day 1 (A and B) day 2 (C and
D) and day 5 (E and F), lungs were harvested; labeled T cells in the lung
parenchyma were enumerated by flow cytometry. Inserts in each panel
show dye fluorescence (x axis) versus forward scatter (y axis) of cells
present in total lung suspensions at the indicated time points. Data are
representative of four independent experiments.1841 Small et al.
ognition (21–23) or the result of the migration of these ac-
tivated effector CD8  T cells out of the lungs to another
site to die (e.g., the liver; references 24–26). However, the
evidence suggesting extensive division of these T cells by
48 h after transfer (Fig. 5 C) raised the possibility that the
cells were still present late in the progression of injury
(days 4–5), but had undergone a sufficient number of divi-
sions (and therefore CFDA-SE dye dilution) to no longer
be detectable.
As an independent criterion for the presence of the
transferred cells in the lungs, we made use of the fact that
the D4 CTLs specifically bind MHC class I tetramers con-
taining the HA210–219 peptide epitope (18). To detect
and enumerate HA-specific T cells, dye-labeled D4 T cells
were adoptively transferred into HA  and control HA 
mice, and lungs were harvested in order to examine infil-
trating cells for HA210–219 tetramer staining and CFDA-
SE dye content at days 1 and 5 after T cell transfer. At day
1, dye-labeled cells which bound HA210–219 tetramer
were readily isolated from the lungs of control mice (Fig. 6
A). Specificity of tetramer staining was determined using an
MHC class I tetramer loaded with a control kd-binding
peptide, derived from murine Jak-1 protein (18) (Fig. 6 B).
By contrast, the majority of labeled cells isolated from the
lungs of HA  mice at day 1 only weakly bound specific
tetramer (Fig. 6 C) at a binding intensity slightly above the
level of background staining observed with the control tet-
ramer (Fig. 6 D). This result, although unexpected, was not
surprising. Several recent reports have documented that en-
gagement of the TCR on CD8  T cells in response to an-
tigen results in the downregulation of cell surface TCR and
a loss of tetramer staining (27–29). At day 5 after transfer,
dye-labeled cells which bound the specific tetramer were
readily enumerated in the lungs of control mice (Fig. 6 E
and F), but few dye-labeled and/or tetramer staining cells
were identified in the lung parenchyma of the transgene-
positive mice at this time (Fig. 6 G and H).
To assess the functional status of transferred T cells
present in the lungs of recipient mice late after transfer, we
examined antigen-dependent IFN-  production by CD8 
T cells isolated at days 4–5 after transfer from the lungs of
control and transgenic mice, in response to in vitro stimu-
lation with the HA210–219 peptide by intracellular IFN- 
staining. As Fig. 7 A demonstrates, CFDA-SE–labeled
CD8  T cells were readily identified in the lungs of con-
Figure 6. Tetramer-binding cells in lung parenchyma. D4 CTLs were
labeled with CFDA-SE dye before transfer into SPC-HA  (control) and
SPC-HA+ (HA transgene) recipients. At day 1 after transfer of 8–10  
106 dye-labeled T cells, mononuclear cells infiltrating the lung paren-
chyma of recipient mice were isolated, and simultaneously examined by
flow cytometry for CFDA-SE dye intensity, and for either HA210 tet-
ramer staining (A and C), or staining by the control Jak-1 tetramer (B and
D). A parallel analysis of dye intensity and HA210 tetramer staining (E
and G) or Jak-1 tetramer (F and H) was performed at day 5 after transfer.
Data shown are for one HA+ and SPC-HA  recipient at each time point
and are representative of three independent experiments where the analy-
sis of tetramer staining was performed.
Figure 7. Ex vivo IFN-  secretion by lung infiltration CD8+ T cells. 5 d
after transfer of 10   106 CFDA-SE–labeled D4 T cells into each of four
SPC-HA  (control) or SPC-HA+ (HA transgene) recipients, pooled pop-
ulations of lung-infiltrating mononuclear cells from HA  and HA+ recipi-
ents were examined directly ex vivo for CD8 expression and CFDA-SE
dye intensity (A and B). In parallel, lung mononuclear cells were stimulated
in vitro with the clone-specific HA210–219 peptide (C and D) or the
control HA204–212 peptide (E and F). Antigen-dependent, intracellular
IFN-  accumulation (y axis), and CFDA-SE dye intensity (x axis) of lung
mononuclear cells was determined by flow cytometry.1842 CTL Effector Activity in Lung Injury
trol, nontransgenic mice and represented the majority of
CD8  T cells isolated from the lungs ( 90%). The dye-
labeled cells produced IFN-  in response to stimulation with
the specific HA210–219 peptide (Fig. 7 C), but not the
control HA204–212 peptide (Fig. 7 E). In SPC-HA  mice
(Fig. 7 B), due to the exuberant inflammatory response in
the lungs, CD8  T cells represent a smaller fraction of the
total lung mononuclear cells than in control recipients
( 10% CD8  T cells in HA  mice versus 30–35% CD8 
T cells in HA  control mice). As expected,  5% of the
CD8  T cells isolated were dye-labeled. Few of CD8  T
cells isolated from the lungs of these mice produced IFN- 
in response to specific peptide in vitro (Fig. 7 D and F) and
the majority of the cells that did were positive for CFDA-
SE staining ( 75%).
Alveolar Type II Cell Status during Injury Progression.
The above analysis suggested that the majority of CD8  T
cells which enter in the lung parenchyma of HA  trans-
genic mice after adoptive transfer are eliminated from the
lungs by 48 h after encounter with the target HA antigen
expressed by alveolar type II cells. This loss of antigen-spe-
cific T cells over time parallels the decline in IFN- 
mRNA levels observed in the lungs after cell transfer (Fig.
4 A). However, pulmonary inflammation increased pro-
gressively over the same time frame. This implies that the
sustained activity of transferred T cells is not required for
injury progression and that the CD8  T cells act early in
the injury process. A potential mechanism which could ex-
plain the need for antigen-specific CTLs only early in the
evolution of the injury process is that these cells encounter
HA-expressing type II cells in the lungs shortly after trans-
fer and induce widespread destruction of the target cells by
direct cytolysis. Inflammatory amplification might then oc-
cur both as a result of type II cell lysis and by release of
proinflammatory mediators by the CD8  T cells in re-
sponse to TCR engagement by antigen.
According to this hypothesis, alveolar type II cells
should be rapidly eliminated from the lungs of HA  mice
after CD8  T cell transfer. However, we recently re-
ported that intact alveolar cells with the morphologic fea-
tures of type II cells were demonstrable in situ in lung sec-
tions up to 48 h after T cell transfer into SP-C HA 
recipients (17). Although CD8  T cell-mediated injury in
this model is evident throughout the lungs (15, 16), the
rate of injury progression and inflammatory cell accumula-
tion in all regions of the lungs may not be uniform. Con-
sequently, analysis of the number and viability of alveolar
type II cells by morphologic criteria in lung sections may
not provide an accurate estimate of the status of these
CD8  T cell targets throughout the lung parenchyma
during injury progression. Furthermore, rapid destruction
of alveolar type II cells by effector T cells early in injury
development (6–24 h) with compensatory regeneration
and hyperplasia of these type late in injury development
(16) could lead to an underestimate of the extent of alveo-
lar type II destruction using only morphologic criteria. To
assess the status of alveolar type II cells globally in the lung
parenchyma during injury progression, we examined the
level of murine surfactant B (SPB) mRNA in whole lung
homogenates from HA  and HA  T cell recipients by
RPA. Since the SPB gene is constitutively expressed pri-
marily in alveolar type II cells (30), the level of SPB mes-
sage is likely to reflect the impact of the transferred CD8 
T cells on type II cell integrity and numbers. As Fig. 8
demonstrates, SPB message levels in both HA  and HA 
recipients was unchanged over the time points sampled (6
through 96 h).
MCP-1 Gene Expression by Type II Cells In Situ. The
above results suggested that alveolar type II cell numbers
throughout the lungs did not fluctuate for up to 96 h after
CD8  T cell transfer. This result is consistent with our pre-
vious findings that the CD8  T cells initiate injury by a
perforin/FasL-independent mechanism (16) and that the
interaction of the effector T cells with HA-expressing alve-
olar type II cells may result in the activation of these cells
(17) rather than their elimination.
Since MCP-1 expression in the lungs was elevated in the
lungs at 72 h after cell transfer (Fig. 4 B) when SP-B ex-
pression by alveolar type II cells was maintained, we asked
if alveolar type II cells expressed MCP-1. To address this,
MCP-1 gene expression was examined in the lung paren-
chyma by in situ hybridization. As Fig. 9 A demonstrates,
the antisense probe for MCP-1 was localized to discrete
sites in the alveoli of SP-C HA  recipient mice corre-
sponding to the distribution of alveolar type II cells in the
alveolar wall (31). The antisense probe did not bind to the
lung parenchyma of HA  nontransgenic mice at 72 h after
T cell transfer (Fig. 9 B). In situ hybridization with the
MCP-1 sense probe demonstrated no specific binding (data
not shown). The discrete pattern of antisense MCP-1
probe localization along the alveolar wall corresponded to
the distribution of HA transgene expression in alveolar type
II cells of SP-C HA  mice using an antisense HA probe
(Fig. 9 C). To further establish by morphology the pres-
ence of alveolar type II cells at 72 h after T cell transfer, we
surveyed the lung parenchyma by electron microscopy.
Fig. 9 D shows a representative view of an inflamed alveo-
lus demonstrating an alveolar type II cell and an associated
inflammatory cell in the alveolar wall.
Figure 8. Kinetics of Surfactant B (SP-B) gene expression in the lungs
after CD8+ T cell transfer. Lungs of transgenic (HA+) and nontransgenic
(HA ) mice were harvested at the indicated times after transfer of 10  
106 cloned D4 CTLs per recipient and lung RNA isolated. SP-B gene ex-
pression was measured by RPA with expression of the L32 housekeeping
gene included as a control for RNA loading. The level of SP-B expres-
sion in control mice not receiving D4 T cells is indicated in lane “-”.1843 Small et al.
Discussion
T cell–mediated clearance of virus infection frequently
involves some degree of injury to the tissue or organ in-
volved, though the relative contributions of the immune
response and the virus infection itself are difficult to deter-
mine. This study was undertaken to examine the evolution
of pulmonary injury in a model of CD8  T cell–mediated
lung injury, uncomplicated by virus infection, and to assess
the fate of the injury-inducing T cells and the target cell
population in the lung parenchyma. The results of this
study indicate: (i) that lung injury is primarily due to anti-
gen recognition by transferred CD8  T cells with little or
no apparent contribution of lymphocytes of recipient ori-
gin recruited to the site of lung inflammation; (ii) that
mononuclear phagocytes are the predominant inflamma-
tory cell type recruited to the lung during the progression
of this form of CD8  T cell–mediated pulmonary inflam-
mation; (iii) that the expression of inflammatory mediators
in the lung is rapid and robust—some mediators (e.g.,
TNF-  and MCP-1) are expressed at sustained levels
throughout the course of injury development while ex-
pression of others (e.g., the T cell cytokine, IFN- ) rapidly
diminishes over time; (iv) that the great majority of injury
inducing T cells are rapidly eliminated from lungs after
transfer (i.e., within 48 h); and (v) that the targets of the
transferred CD8  T cells (i.e., the transgene-expressing al-
veolar type II cells) appear not to be significantly dimin-
ished in numbers as a result of encounter with the CTLs
and are induced in situ to upregulate expression of the
chemokine MCP-1.
Recently, a number of reports have examined the CD8 
T cell response and the development of CD8  T cell effec-
tors during acute virus infection (8). These reports suggest
that there is a rapid generation and expansion of activated
CD8  CTL effectors in response to antigen. The effector
CD8  T cells migrate to the site of virus infection and are
then eliminated with the resolution of infection. Available
evidence suggests that the effector T cells may either un-
dergo activation-induced cell death in response to antigen
(and die in situ) or leave the site of infection and migrate to
the liver where the activated T cells are eliminated (24, 26).
The model system described here is similar to acute infec-
tion in that cloned activated CD8  T cells after adoptive
transfer reside in a site of target antigen expression (i.e., the
transgene-positive lung) where the T cells encounter and
Figure 9. MCP-1 gene expres-
sion and alveolar type II cell localiza-
tion. Frozen sections of lung tissue
from SPC-HA+ (A) and nontrans-
genic SPC-HA  (B) at 72 h after D4
T cell transfer were hybridized in
situ with 3[H]-labeled antisense and
sense RNA probes specific for the
murine MCP-1 gene (mRNA posi-
tive cells in dark field view: bright
grain aggregates [arrows] overlying
lung parenchyma with antisense
probe). Original magnification:  250.
(C) In situ hybridization of SPC-
HA+ lung tissue with 3[H]-labeled
antisense probe for influenza HA
mRNA. Original magnification:
 250. (D) EM section of fixed in-
flamed alveolar wall at 72 h after T
cell transfer showing alveolar type II
cell (x), infiltrating mononuclear in-
flammatory cell (y), and pulmonary
capillary (z). Original magnification:
 8,000.1844 CTL Effector Activity in Lung Injury
respond to the HA antigen. The fact that most of these ac-
tivated effector T cells are not detected in lungs after 24–48 h
is not surprising since, like activated effector cells present in
lungs during acute viral infection, the transferred T cells
would be eliminated after antigen encounter. In this model
using whole body   ray imaging of the distribution of ra-
diolabeled CD8  CTLs, we have documented that the ma-
jority of transferred T cells ( 80%) migrate from the lungs
to the liver by 24–36 h after transfer (unpublished data).
That the transferred T cells are responding to HA antigen
in the lung is supported by the findings of decreased tet-
ramer staining and diminished CFDA-SE content selec-
tively by cells resident in the lungs of transgene-positive re-
cipients at early times after cell transfer. Of particular
interest is the fact that pulmonary inflammation and injury
progress without the continual presence and sustained ac-
tivity of the antigen-specific CD8  T cells in the lungs.
The finding that SPB mRNA levels in HA  lungs was
unaffected by the transferred CD8  T cell recognition is
also noteworthy. The expression of the murine SP-B gene
has been reported not to be influenced by inflammatory
injury to the lungs (30). However, systemic T cell activa-
tion or acute pulmonary injury has been reported to lead
to the downregulation of murine SP-B expression in lung
tissue (32, 33). Also, in cultured alveolar cells, exposure to
inflammatory cytokines (e.g., IFN- , TNF- ) results in
suppression of SP-B gene expression (34). Furthermore,
rapid destruction of alveolar type II cells by cell-associated
or soluble T cell effector molecules shortly after T cell
transfer could result in the compensatory hyperplasia of re-
sidual type II cells in response to injury. In using SP-B
gene expression to monitor alveolar type II cell numbers
and function, we wanted to survey this cell population in
situ throughout the lung parenchyma to avoid any poten-
tial bias inherent in the morphological evaluation of the vi-
ability and numbers of these cells due to the sampling. By
evaluating SP-B expression both at the onset of lung injury
development (6 h) and as injury evolved (24–96 h), we
hoped to detect any fluctuation in alveolar type II cell
numbers or function during the course of injury develop-
ment as a result of cell death or effects of inflammatory
mediators. The absence of such fluctuations in SP-B ex-
pression in this analysis suggests that early in injury devel-
opment (i.e., day 1–4), type II cells are viable and capable
of producing inflammatory mediators in response to recog-
nition by T cells. In this connection, we have previously
reported morphologic evidence of alveolar type II cell loss
and compensatory type II cell hyperplasia in this model by
EM (15). This data was obtained at days 5–6 after cell
transfer when inflammation and necrosis of inflamed alve-
olar walls was extensive (15). Both type II cell loss and re-
generation could be occurring simultaneously in response
to the massive and diffuse pulmonary injury present at this
late time. Our data suggest that earlier in the evolution of
injury (48–72 h), when alveolar wall necrosis is not promi-
nent, alveolar type II cells are viable and capable of pro-
ducing inflammatory mediators (Figs. 8 and 9) important
in injury progression (17).
In many adoptive transfer models of T cell–mediated tis-
sue injury (or pathogen clearance), the extent of tissue in-
jury (or efficiency of pathogen clearance) is dependant
upon the number of effector T cells transferred. We also
reported a similar CD8  T cell dose dependence of injury
development in this model of pulmonary inflammation and
injury (14) with lower transferred cell innocula ( 5   106
cells) resulting in sublethal injury, minimal weight loss,
moderate pulmonary inflammation, a decreased inflamma-
tory mediator expression in the lungs, (references 15 and
16; unpublished data). The cell dose dependence of injury
development is not directly compatible with a mechanism
of a CD8  T cell–mediated injury where the effector T
cells in the lung recycle and encounter multiple target cells
before their elimination. According to this mechanism, the
transfer of lower cell innoculum should also result in pro-
gressive and ultimately lethal pulmonary injury, but over a
more protracted time course. The results reported here
suggest a mechanism where the effector T cells initiate the
injury process in the lungs and then are rapidly eliminated
from the injury site. Accordingly, the extent of injury
would be dependant on the number of T cells transferred.
Both the rapid elimination of the transferred effector
CD8  T cells and the uniform SP-B expression over the
first 96 h of injury development support the idea that the
interaction of the CTL with alveolar type II target cells in
situ is nonlytic and are consistent with our previous finding
that the expression of cell-associated cytolytic machinery
(e.g., perforin or FasL) by the transferred T cells is not re-
quired for injury development (16). There is evidence from
models of virus specific CD8  T cell responses suggesting
that virus clearance by CD8  CTLs in vivo can be medi-
ated by mechanisms which do not require direct CTL-
mediated lysis of virus-infected cells (1, 35). Similarly, in a
transgenic model of hepatitis B virus (HBV) infection, ex-
pression of the HBV genome is suppressed through a non-
lytic cytokine-mediated interaction between CTL effectors
and hepatocytes in vivo (36). In this connection, it should
be emphasized that the expression of a CTL target antigen
as a transgene in a tissue site does not necessarily reflect the
milieu in which an effector CD8  T cell encounters anti-
gen displayed on virus-infected cells. Inflammatory media-
tors released by virus-infected cells and/or cells of the in-
nate immune system in response to active infection could
increase the sensitivity of target cells to direct cytolysis by
CTLs. Nevertheless, our findings suggest that a nonlytic
cell/cell interaction between effector T cells and target cells
may result in the activation of the target cells in situ and
their participation in the inflammation process (37).
The loss of IFN-  gene expression observed in the lungs
of HA  recipients over time after T cell transfer is readily
attributable to the progressive elimination of functional
HA-specific CD8  T cells early in the evolution of pulmo-
nary injury. In contrast to the transgenic model of HBV in-
fection (1, 36), CD8  T cell–derived IFN-  appears not to
play a critical role in vivo since HA-specific CTL effectors
genetically deficient in IFN-  production efficiently ini-
tiate the development of lethal pulmonary injury after1845 Small et al.
adoptive transfer (unpublished data). However, TNF- ,
which is produced by a diverse array of cell types including
activated CD8  T cells in response to antigen recognition
(38, 39), is expressed at an elevated level throughout the
course of injury development. TNF-  produced in an anti-
gen-dependent fashion by the transferred T cells may be
crucial in the initial phase of injury in this model (17). The
persistent TNF-  gene expression evident during evolu-
tion of injury and inflammation presumably reflects the
production of this cytokine by other cell types in the in-
flamed lung. The likely source of this TNF-  is activated
mononuclear cells of monocyte/macrophage origin ac-
tively recruited into the injured lungs through the action of
MCP-1 and other chemotactic factors. The definitive dem-
onstration that recruited macrophages are the source of this
TNF-  awaits more detailed analysis.
A possible link between macrophage influx into the in-
jured lung and nonlytic recognition of alveolar type II cells
by the transferred T cells comes from the analysis of the ki-
netics of MCP-1 expression in the lungs of HA  recipients.
Like TNF- , the expression of this chemokine gene in the
SPC-HA  lungs increases extremely rapidly after adoptive
transfer, and only slowly decreases throughout the evolu-
tion of pulmonary injury. MCP-1 is a potent chemoattrac-
tant of mononuclear phagocytes (37, 40). Unlike TNF- 
and IFN- , this chemokine is not produced by activated
D4 T cells or other cloned murine CD8  T cells (reference
17; unpublished data). However, MCP-1 gene expression
is upregulated and MCP-1 protein is secreted by cultured
alveolar type II cells in response to an antigen-specific in-
teraction with CD8  CTL effectors in vitro (17). We show
here that, 72 h after CD8  T cell transfer in SPC-HA
mice, MCP-1 gene expression can be detected in situ in al-
veolar wall epithelial cells with the morphological and ana-
tomic distribution of HA  alveolar type II cells. The sus-
tained production of MCP-1 by the activated alveolar type
II cells would contribute to the activation and recruitment
of mononuclear phagocytes to the site of injury, and pro-
mote injury progression even after CTL effector cells are
eliminated. Once activated, the production of inflamma-
tory mediators by the activated, recruited macrophages
would lead, in turn, to further amplification of inflamma-
tion and progressive injury to the lungs.
In conclusion, the results reported here provide insight
into the process of inflammatory lung injury mediated by
CD8  T cells which may be applicable both to pulmonary
virus infection and to other inflammatory lung injuries
where CD8  T cells have been implicated. Accordingly,
effector CD8  T cells need not function continuously, but
need only function transiently to initiate the development
of progressive lung injury. Nonlytic interactions between
effector CD8  T cells and target cells in vivo in the lung
could result in the transient activation of the target cells in
situ and their participation in the amplification of the injury
process through the recruitment and activation of inflam-
matory cells. In the case of acute virus infection in the lung,
the extent of virus replication in the lungs before the gen-
eration and recruitment of activated CD8  T cell effectors
to the site of infection would be crucial to the ultimate
outcome of infection. When virus replication is extensive,
potent effector CD8  T cells (even if only transiently
present and active) would trigger an inflammatory cascade
of sufficient magnitude to promote extensive and poten-
tially lethal injury—even in the face of effective viral clear-
ance by lytic and nonlytic CD8  T cell effector mecha-
nisms (1, 35, 39). Therefore, therapeutic control of acute
virus infection may require intervention not only at the
level of virus replication, but also at the level of the host
immune response. A corollary implication is that rapid
elimination of T cell effectors may occur in the absence of
antigen clearance, as might be expected in autoimmune
disease, with continued inflammation despite the absence
of antigen-specific cells.
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